Evidence map›Paper›PMID 39069016›Full record

Trial reportJournal of vascular surgery2024

The impact of revascularization strategy on clinical failure, hemodynamic failure, and chronic limb-threatening ischemia symptoms in the BEST-CLI Trial.

Matthew T Menard, Alik Farber, Gheorghe Doros, Katherine L McGinigle, Emiliano Chisci, Leonardo C Clavijo, Ahmed Kayssi, Peter A Schneider, Beau M Hawkins, Michael D Dake and 4 more

Abstract readRandomized Controlled TrialComparative StudyMulticenter Study
In one paragraph

Trial report in Journal of vascular surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Early Improvement in Wound, Ischaemia, and foot Infection (WIfI) Ischaemia Grade Lowers Risk of Major Amputation following Revascularisation for Chronic Limb Threatening Ischaemia.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matthew T MenardDivision of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: mmenard@bwh.harvard.edu.
Alik FarberDivision of Vascular and Endovascular Surgery, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Gheorghe DorosSchool of Public Health, Boston University, Boston, MA.
Katherine L McGinigleDivision of Vascular Surgery, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Emiliano ChisciDepartment of Surgery, Vascular Surgery Division, San Giovanni di Dio Hospital, Florence, Italy.
Leonardo C ClavijoCoastal Cardiology, French Hospital Medical Center, San Luis Obispo, CA.
Ahmed KayssiDivision of Vascular Surgery, University of Toronto, Toronto, ON, Canada.
Peter A SchneiderDivision of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, CA.
Beau M HawkinsCardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Michael D DakeDepartment of Medical Imaging, University of Arizona Health Sciences, Tucson, AZ.
Taye HamzaHealthCore, Inc, Watertown, MA.
Michael B StrongDivision of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Kenneth RosenfieldSection of Vascular Medicine and Intervention Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Michael S ConteDivision of Vascular and Endovascular Surgery, University of California, San Francisco, San Francisco, CA.

Funding

BEST-CLI Trial-DCCU01HL107407 · NHLBI · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI ASSMANN, SUSAN FERA, CZIRAKY, MARK J. · 2013 to 2019
$20.0M
BEST-CLI Trial-CCC-LeadU01HL107352 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FARBER, ALIK, MENARD, MATTHEW THOMAS · 2013 to 2018
$6.1M
BEST-CLI Trial - Cost-Effectiveness of Treatments for Critical Limb IschemiaU01HL115662 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHOUDHRY, NITEESH K · 2013 to 2018
$1.2M
Machine learning-based staging system to predict chronic limb-threatening ischemia disease progression and survival: A secondary analysis of the BEST-CLI trial dataR21HL172091 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCGINIGLE, KATHARINE L · 2024 to 2025
$233k
NHLBI NIH HHS R21 HL172091NHLBI NIH HHS U01 HL107352NHLBI NIH HHS U01 HL107407NHLBI NIH HHS U01 HL115662
6 · The paper itself

Abstract

objectiveSustained clinical and hemodynamic benefit after revascularization for chronic limb-threatening ischemia (CLTI) is needed to resolve symptoms and prevent limb loss. We sought to compare rates of clinical and hemodynamic failure as well as resolution of initial and prevention of recurrent CLTI after endovascular (ENDO) vs bypass (OPEN) revascularization in the Best-Endovascular-versus-best-Surgical-Therapy-in-patients-with-CLTI (BEST-CLI) trial.

methodsAs planned secondary analyses of the BEST-CLI trial, we examined the rates of (1) clinical failure (a composite of all-cause death, above-ankle amputation, major reintervention, and degradation of WIfI stage); (2) hemodynamic failure (a composite of above-ankle amputation, major and minor reintervention to maintain index limb patency, failure to an initial increase or a subsequent decrease in ankle brachial index of 0.15 or toe brachial index of 0.10, and radiographic evidence of treatment stenosis or occlusion); (3) time to resolution of presenting CLTI symptoms; and (4) incidence of recurrent CLTI. Time-to-event analyses were performed by intention-to-treat assignment in both trial cohorts (cohort 1: suitable single segment great saphenous vein [SSGSV], N = 1434; cohort 2: lacking suitable SSGSV, N = 396), and multivariate stratified Cox regression models were created.

resultsIn cohort 1, there was a significant difference in time to clinical failure (log-rank P < .001), hemodynamic failure (log-rank P < .001), and resolution of presenting symptoms (log-rank P = .009) in favor of OPEN. In cohort 2, there was a significantly lower rate of hemodynamic failure (log-rank P = .006) favoring OPEN, and no significant difference in time to clinical failure or resolution of presenting symptoms. Multivariate analysis revealed that assignment to OPEN was associated with a significantly lower risk of clinical and hemodynamic failure in both cohorts and a significantly higher likelihood of resolving initial and preventing recurrent CLTI symptoms in cohort 1, including after adjustment for key baseline patient covariates (end-stage renal disease [ESRD], prior revascularization, smoking, diabetes, age >80 years, WIfI stage, tissue loss, and infrapopliteal disease). Factors independently associated with clinical failure included age >80 years in cohort 1 and ESRD across both cohorts. ESRD was associated with hemodynamic failure in cohort 1. Factors associated with slower resolution of presenting symptoms included diabetes in cohort 1 and WIfI stage in cohort 2.

conclusionsDurable clinical and hemodynamic benefit after revascularization for CLTI is important to avoid persistent and recurrent CLTI, reinterventions, and limb loss. When compared with ENDO, initial treatment with OPEN surgical bypass, particularly with available saphenous vein, is associated with improved clinical and hemodynamic outcomes and enhanced resolution of CLTI symptoms.

Indexed as

Amputation, SurgicalEndovascular ProceduresHemodynamicsPeripheral Arterial DiseaseRecurrenceTreatment FailureVascular PatencyAgedAnkle Brachial IndexChronic DiseaseChronic Limb-Threatening IschemiaFemaleHumansIschemiaLimb SalvageMaleCritical limb-threatening ischemiaEndovascularHemodynamicPeripheral artery diseaseRevascularizationSurgical bypassWIfIWound healing

Identifiers

PMID39069016
PMCPMC11734614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.